Meningococcal Infection and NMOSD

Key Takeaways

• Eculizumab and ravulizumab increase meningococcal infection risk, necessitating vaccination in treated patients.
• Phase 3 and long-term studies emphasize the need for vigilant monitoring and prophylactic measures despite vaccination.
• Breakthrough infections can occur even with vaccination, highlighting the need for ongoing risk assessment.
• The impact of meningococcal vaccination on disease relapse activity requires further investigation.